Cargando…

Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden

BACKGROUND: Worldwide, coronary heart disease accounts for 7 million deaths each year. In Sweden, acute coronary syndrome (ACS) is a leading cause of hospitalization and is responsible for 1 in 4 deaths. OBJECTIVE: The aim of this analysis was to assess the cost-effectiveness of rivaroxaban 2.5 mg t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Begum, Najida, Stephens, Stephanie, Schoeman, Olaf, Fraschke, Anina, Kirsch, Bodo, Briere, Jean-Baptiste, Verheugt, Freek W. A., van Hout, Ben A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675751/ https://www.ncbi.nlm.nih.gov/pubmed/26099515 http://dx.doi.org/10.1007/s40119-015-0041-3

Ejemplares similares

Cost of illness of atrial fibrillation: a nationwide study of societal impact
por: Johnsen, Søren Paaske, et al.
Publicado: (2017)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
por: Cowie, Martin R, et al.
Publicado: (2020)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade
por: Atar, Dan, et al.
Publicado: (2014)

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
por: Soini, Erkki, et al.
Publicado: (2020)

Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles
por: Gibson, Edward, et al.
Publicado: (2016)

Anticoagulation in patients with mechanical heart valves: follow the guidelines!
por: Verheugt, Freek W.A.
Publicado: (2015)

Potential role of rivaroxaban in patients with acute coronary syndrome
por: Fitchett, David H
Publicado: (2012)

Resolution of Extensive Coronary Thrombosis under Rivaroxaban Treatment
por: Yuksel, Murat, et al.
Publicado: (2015)

Successful Treatment and Secondary Prevention of Venous Thrombosis Secondary to Behçet Disease with Rivaroxaban
por: Boban, Ana, et al.
Publicado: (2016)

Suspected Rivaroxaban-Induced Anaphylaxis Secondary to Ingestion of Rivaroxaban and Nimesulide Without Cross-Reactivity to Dabigatran – A Case Report
por: Gumbis, Gediminas, et al.
Publicado: (2023)

Spontaneous rupture and hematoma of the sartorius muscle secondary to rivaroxaban therapy
por: Ardebol, Javier, et al.
Publicado: (2020)

Spontaneous haemorrhagic cholecystitis secondary to the use of novel anticoagulants (rivaroxaban)
por: Kurian, Merina, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021)

Effectiveness of two intensive treatment methods for smoking cessation and relapse prevention in patients with coronary heart disease: study protocol and baseline description
por: Berndt, Nadine, et al.
Publicado: (2012)

The role of aspirin in women’s health
por: Verheugt, Freek WA, et al.
Publicado: (2011)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
por: Feng, Tianyu, et al.
Publicado: (2022)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience
por: Agarwal, Ajay, et al.
Publicado: (2013)

Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole
por: Bennison, Craig, et al.
Publicado: (2016)

Resolution of Left Ventricular Thrombus Secondary to Tachycardia-Induced Heart Failure with Rivaroxaban
por: Nakasuka, Kosuke, et al.
Publicado: (2014)

Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report
por: Shastri, Pinang, et al.
Publicado: (2020)

A Complicated Case of Transient Constrictive Pericarditis Secondary to Rivaroxaban-Associated Hemopericardium
por: Jain, Vardhmaan, et al.
Publicado: (2020)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
por: Clay, Emilie, et al.
Publicado: (2018)

Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review
por: Gibson, Edward, et al.
Publicado: (2016)

Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden
por: Jamookeeah, Clare, et al.
Publicado: (2016)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
por: Landmesser, Ulf, et al.
Publicado: (2020)

Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
por: Arashi, Hiroyuki, et al.
Publicado: (2022)

Characterization of secondary care for COPD in Sweden
por: Sundh, Josefin, et al.
Publicado: (2017)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Atrial fibrillation: the cost of illness in Sweden
por: Ericson, Lisa, et al.
Publicado: (2010)

The societal costs of problem gambling in Sweden
por: Hofmarcher, T., et al.
Publicado: (2020)

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
por: Margolis, Jay M., et al.
Publicado: (2016)

Decline in Coronary Mortality in Sweden between 1986 and 2002: Comparing Contributions from Primary and Secondary Prevention
por: Björck, Lena, et al.
Publicado: (2015)

Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease
por: Stephens, Stephanie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fpqlg7utf6p6b9h2kbriv8e417